Cardium Gets Strategic Funding From China

San Diego-based Cardium Therapeutics said Monday that it has scored a strategic funding from Shanxi Taxus Pharmaceuticals Co., Ltd., to help support development of its regenerative medicine therapeutics products. According to Cardium, the deal is worth up to $5.0M to support commercialization of its products. The publicly traded company said it will change its name to Taxus Cardium Pharmaceuticals Group in connection with the deal. More information »